1. Home
  2. NVO

NVO

Novo Nordisk A/S

Logo Novo Nordisk A/S

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Founded: 1923 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 572.9B IPO Year: N/A
Target Price: $133.00 AVG Volume (30 days): 5.1M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: 0.66% Dividend Payout Frequency: Semi-Annual
EPS: 2.66 EPS Growth: 52.25
52 Week Low/High: $75.56 - $138.28 Next Earning Date: 05-02-2024
Revenue: $33,189,791,603 Revenue Growth: 31.26%
Revenue Growth (this year): 25.49% Revenue Growth (next year): 20.76%

Share on Social Networks:

Similar to NVO Stocks: